Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Palisade Bio Inc (PALI)

Palisade Bio Inc (PALI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,737
  • Shares Outstanding, K 21,880
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,620 K
  • 60-Month Beta 1.65
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.74
Trade PALI with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.92
  • Most Recent Earnings -0.26 on 05/13/22
  • Next Earnings Date 08/23/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -4.10
  • Growth Rate Est. (year over year) +24,465.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4300 unch
on 06/29/22
0.6199 -30.63%
on 06/06/22
-0.0820 (-16.02%)
since 05/27/22
3-Month
0.4000 +7.50%
on 05/09/22
1.1600 -62.93%
on 03/30/22
-0.6700 (-60.91%)
since 03/29/22
52-Week
0.4000 +7.50%
on 05/09/22
4.3300 -90.07%
on 07/13/21
-3.7100 (-89.61%)
since 06/29/21

Most Recent Stories

More News
Palisade Bio Initiates Phase 3 Study of LB1148 in Lead Indication for Postoperative Return of Bowel Function

Completion of enrollment for Phase 3 study targeted within 18-24 months In multiple clinical studies, LB1148 has demonstrated statistically significant...

PALI : 0.4300 (-3.37%)
Palisade Bio to Present at the 2022 BIO International Convention

In-person presentation on Monday, June 13th at 1:45 PM PT...

PALI : 0.4300 (-3.37%)
Palisade Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update

Phase 3 study of LB1148 in lead indication for postoperative return of bowel function on track to commence Q2 2022 Ongoing Phase 2 study of LB1148 for...

PALI : 0.4300 (-3.37%)
Palisade Bio Announces Inducement Awards Under Inducement Plan for Key New Hires

CARLSBAD, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical-stage biopharmaceutical company advancing therapies for acute...

PALI : 0.4300 (-3.37%)
Palisade Bio Announces $2.0 Million Registered Direct Offering

CARLSBAD, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company” or “Palisade Bio”), a clinical-stage...

PALI : 0.4300 (-3.37%)
Palisade Bio and Newsoara Receive NMPA Clearance to Commence Phase 3 Clinical Trial in China Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery

NMPA clearance expands global Phase 3 clinical development program; Company recently announced clearance from U.S. Food and Drug Administration to commence...

PALI : 0.4300 (-3.37%)
Palisade Bio Provides Business Outlook and Highlights Expected Near-Term Pipeline Advancements

Phase 3 study of LB1148 in lead indication for postoperative return of bowel function on track to commence Q2 2022...

PALI : 0.4300 (-3.37%)
Palisade Bio to Participate in the Virtual Investor Management and KOL Roundtable Event

Live moderated video webcast discussion among members of Management and a renowned Key Opinion Leader on Tuesday, May 3rd at 10:00 AM ET...

PALI : 0.4300 (-3.37%)
Palisade Bio (Nasdaq: PALI) to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group and Hosted by M-Vest

CARLSBAD, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies...

PALI : 0.4300 (-3.37%)
Top Penny Stocks Today: Why DPRO, PALI, ENSV, SPCB and SMFL Are Up Today

There's more than just heavy trading pushing penny stocks higher today

SMFL : 0.6599 (+4.25%)
DPRO : 0.8729 (-6.16%)
SPCB : 0.3450 (+4.96%)
PALI : 0.4300 (-3.37%)
ENSV : 2.13 (+1.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Palisade Bio Inc. is a late-stage biopharma company advancing therapies which help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio Inc., formerly known as Seneca Biopharma Inc., is based in CARLSBAD, Calif.

See More

Key Turning Points

3rd Resistance Point 0.5250
2nd Resistance Point 0.5060
1st Resistance Point 0.4680
Last Price 0.4300
1st Support Level 0.4110
2nd Support Level 0.3920
3rd Support Level 0.3540

See More

52-Week High 4.3300
Fibonacci 61.8% 2.8287
Fibonacci 50% 2.3650
Fibonacci 38.2% 1.9013
Last Price 0.4300
52-Week Low 0.4000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar